CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHEMOIMMUNE
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 08 Jun 2017 Planned initiation date changed from 30 May 2017 to 27 Jun 2017.
- 08 May 2017 New trial record